glp-1 obesity news The rate in the US fell in 2023 as GLP-1s go mainstream US adult obesity rate drops
Description
Risk of bias: all four RCTs were rated low risk by RoB2 (with some concerns for open-label outcome ascertainment in three trials, a domain-specific issue that does not alter the overall RoB2 category from low)
The incretin system has become an important target in the treatment of type 2 diabetes in recent years, and glucagon-like peptide 1 (GLP-1) is of particular interest for its glucose-lowering effects
Free consultation.
Get exposed to over 2100 subscribers globally, most of whom are investors.
If youve started to notice you
